Works matching DE "PROTEIN-tyrosine kinase inhibitors"
Results: 5000
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer.
- Published in:
- BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-03989-0
- By:
- Publication type:
- Article
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35746
- By:
- Publication type:
- Article
Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective.
- Published in:
- Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-01864-1
- By:
- Publication type:
- Article
Chemotherapy-induced leg ulcers: a case series.
- Published in:
- Journal of Wound Care, 2025, v. 34, n. 3, p. 250, doi. 10.12968/jowc.2020.0128
- By:
- Publication type:
- Article
Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3).
- Published in:
- Cancer Management & Research, 2025, v. 17, p. 103, doi. 10.2147/CMAR.S484947
- By:
- Publication type:
- Article
Isolated Central Nervous System Infiltrated and Progressed to Acute Myeloid Leukemia from Chronic Myeloid Leukemia with e1a3 BCR-ABL1 Transcript: A Rare Case Report and Literature Review.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
YAP acts as an independent prognostic marker and regulates growth and metastasis of gastrointestinal stromal tumors via FBXW7-YAP pathway.
- Published in:
- Journal of Gastroenterology, 2025, v. 60, n. 3, p. 275, doi. 10.1007/s00535-024-02180-1
- By:
- Publication type:
- Article
Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.
- Published in:
- BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13775-z
- By:
- Publication type:
- Article
A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing.
- Published in:
- Pathology & Oncology Research, 2025, p. 1, doi. 10.3389/pore.2025.1611964
- By:
- Publication type:
- Article
Artificial intelligence can be trained to predict c-KIT -11 mutational status of canine mast cell tumors from hematoxylin and eosin-stained histological slides.
- Published in:
- Veterinary Pathology, 2025, v. 62, n. 2, p. 152, doi. 10.1177/03009858241286806
- By:
- Publication type:
- Article
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04755-y
- By:
- Publication type:
- Article
Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
Autophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 2, p. 215, doi. 10.3390/biom15020215
- By:
- Publication type:
- Article
Pain mediator NGF improves chondrocyte extracellular matrix synthesis via PI3K/AKT pathway.
- Published in:
- Journal of Orthopaedic Surgery & Research, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13018-025-05503-x
- By:
- Publication type:
- Article
Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors.
- Published in:
- Pharmaceutics, 2025, v. 17, n. 2, p. 260, doi. 10.3390/pharmaceutics17020260
- By:
- Publication type:
- Article
Oral Administration of Neratinib Maleate-Loaded Lipid–Polymer Hybrid Nanoparticles: Optimization, Physical Characterization, and In Vivo Evaluation.
- Published in:
- Pharmaceutics, 2025, v. 17, n. 2, p. 221, doi. 10.3390/pharmaceutics17020221
- By:
- Publication type:
- Article
Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 262, doi. 10.3390/ph18020262
- By:
- Publication type:
- Article
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 696, doi. 10.3390/cancers17040696
- By:
- Publication type:
- Article
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 668, doi. 10.3390/cancers17040668
- By:
- Publication type:
- Article
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 563, doi. 10.3390/cancers17040563
- By:
- Publication type:
- Article
Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1489210
- By:
- Publication type:
- Article
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors.
- Published in:
- Hematology Reports, 2025, v. 17, n. 1, p. 7, doi. 10.3390/hematolrep17010007
- By:
- Publication type:
- Article
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 470, doi. 10.3390/biomedicines13020470
- By:
- Publication type:
- Article
Effect of Hemoglobin, Albumin, Lymphocyte Count, and Platelet (HALP) Score on Survival of Patients with Metastatic Thyroid Cancer Treated with Tyrosine Kinase Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1306, doi. 10.3390/jcm14041306
- By:
- Publication type:
- Article
The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1149, doi. 10.3390/jcm14041149
- By:
- Publication type:
- Article
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 207, doi. 10.1007/s00277-024-06100-4
- By:
- Publication type:
- Article
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 361, doi. 10.1007/s00277-024-06033-y
- By:
- Publication type:
- Article
Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 26, doi. 10.1159/000541936
- By:
- Publication type:
- Article
Downregulation of Rad51 Expression and Activity Potentiates the Cytotoxic Effect of Osimertinib in Human Non-Small Cell Lung Cancer Cells.
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 12, doi. 10.1159/000540867
- By:
- Publication type:
- Article
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 97, doi. 10.3390/curroncol32020097
- By:
- Publication type:
- Article
Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy.
- Published in:
- World Journal of Surgical Oncology, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12957-025-03707-3
- By:
- Publication type:
- Article
Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1776, doi. 10.3390/ijms26041776
- By:
- Publication type:
- Article
Single-Cell RNA Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New Perspectives.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1483, doi. 10.3390/ijms26041483
- By:
- Publication type:
- Article
Design, Synthesis and Biological Activity Study of γ-Aminobutyric Acid (GABA) Derivatives Containing Bridged Bicyclic Skeletons as BCAT1 Inhibitors.
- Published in:
- Molecules, 2025, v. 30, n. 4, p. 904, doi. 10.3390/molecules30040904
- By:
- Publication type:
- Article
Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review).
- Published in:
- Medicine International (2754-3242), 2025, v. 5, n. 2, p. 1, doi. 10.3892/mi.2024.212
- By:
- Publication type:
- Article
Current and emerging immunobiologic therapies for atopic dermatitis.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 226, doi. 10.1007/s40267-024-01075-8
- By:
- Publication type:
- Article
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 2, p. 45, doi. 10.1007/s40267-023-01041-w
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 357, doi. 10.1007/s40267-023-01025-w
- By:
- Publication type:
- Article
Renal Cancer.
- Published in:
- Current Medical Literature: Urology, 2012, v. 18, n. 1, p. 27
- Publication type:
- Article
Renal Cancer.
- Published in:
- Current Medical Literature: Urology, 2010, v. 16, n. 2, p. 58
- Publication type:
- Article
The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review.
- Published in:
- Veterinary & Comparative Oncology, 2022, v. 20, n. 2, p. 362, doi. 10.1111/vco.12799
- By:
- Publication type:
- Article
Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
- Published in:
- Veterinary & Comparative Oncology, 2022, v. 20, n. 1, p. 142, doi. 10.1111/vco.12756
- By:
- Publication type:
- Article
Expression of VEGFR and PDGFR-α/- β in 187 canine nasal carcinomas.
- Published in:
- Veterinary & Comparative Oncology, 2017, v. 15, n. 3, p. 1041, doi. 10.1111/vco.12245
- By:
- Publication type:
- Article
Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2017, v. 15, n. 3, p. 890, doi. 10.1111/vco.12230
- By:
- Publication type:
- Article
A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
- Published in:
- Veterinary & Comparative Oncology, 2016, v. 14, n. 4, p. 361, doi. 10.1111/vco.12116
- By:
- Publication type:
- Article
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
- Published in:
- Veterinary & Comparative Oncology, 2015, v. 13, n. 3, p. 314, doi. 10.1111/vco.12053
- By:
- Publication type:
- Article
European consensus document on mast cell tumours in dogs and cats.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. e1, doi. 10.1111/j.1476-5829.2012.00341.x
- By:
- Publication type:
- Article
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 163, doi. 10.1111/j.1476-5829.2012.00342.x
- By:
- Publication type:
- Article
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines*.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 223, doi. 10.1111/j.1476-5829.2012.00335.x
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor special issue Tyrosine kinase inhibitor special issue.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 161, doi. 10.1111/j.1476-5829.2012.00339.x
- By:
- Publication type:
- Article